2018 Fiscal Year Final Research Report

Development of suicide gene stem cell therapy by non-viral gene transfer method and application to glioma therapy

Research Project

PDF

Project/Area Number	16K10752
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Neurosurgery
Research Institution	Hamamatsu University School of Medicine
Principal Investigator	sameshima tetsuro 浜松医科大学, 医学部, 講師 (00295213)
Co-Investigator(Kenkyū-buntansha)	難波宏樹浜松医科大学, 医学部, 教授 (60198405) 山崎友裕浜松医科大学, 医学部附属病院, 助教 (40781050) 小泉慎一郎浜松医科大学, 医学部附属病院, 助教 (10456577)
Project Period (FY)	2016-04-01 – 2019-03-31
Keywords	自殺遺伝子幹細胞療法 / HSVｔｋ/GCV　ｓｙｓｔｅｍ / ＰｉｇｇｙＢａｃ　system
Outline of Final Research Achievements	We tried to transfect the episomal vector with HSVtk gene to stem cells, aiming at the development of stem cell therapy for glioblastoma by non-viral gene transfer method. However, that did not go well because the size of the episomal vector was too large, leading to the low transfer efficiency. So we have devised a non-viral method using another system in which the transgenes are integrated into the host gene. The immortalizing gene is co-transfected in order to achieve immortalization of HSVtk-expressiong stem cells. The mesenchymal stem cells as the vehicle are provided by the company that performs cell preparation based on GMP standards. We have already confirmed the sufficient migratory capacity and cell proliferation ability of the stem cells. We have also prepared the plasmids of several patterns with the combination of the HSVtk, hygromycin, GFP and immotalizing gene so as not to be overlarge size. We are under plasmid transfection by electroporation and lipofection methods.
Free Research Field	脳腫瘍
Academic Significance and Societal Importance of the Research Achievements	ウイルスベクターを用いた遺伝子導入細胞は製剤化を考慮した場合、臨床使用が可能な安全で純度の高い製剤を作成可能な施設は非常に限定されている。そこで非ウイルス的HSVtk遺伝子導入幹細胞株の樹立を目指し本研究を着想した。エピソーマルベクターは自己増殖可能なプラスミドベクターであり、本プラスミドを用いた新規治療法の実現が期待されたがベクターサイズの壁に阻まれ断念した。しかし、引き続き考案したpiggyBacシステムは同様に非ウイルス的遺伝子導入法であるだけでなく、宿主遺伝子に安定的に目的遺伝子が挿入される手法であり、本法は有効性が高く、安全で高品質な細胞製剤の低コスト新規作成法となる。